Literature DB >> 338218

Circulating T-cell numbers and their mitogenic potential in leprosy--correlation with mycobacterial load.

I Nath, J Curtis, A K Sharma, G P Talwar.   

Abstract

The effect of treatment and mycobacterial load on circulating T-cell numbers and their functional ability was investigated in forty-one patients with leprosy. Both early binding T cells and their responses to phytohaemagglutinin (PHA), concanavalin A (Con A) and pokeweed mitogen (PWM) were profoundly and uniformly depressed in untreated, and partially treated, bacilleferous lepromatous leprosy (LL) patients as compared with normal subjects and tuberculoid patients. On elimination of mycobacteria, subsequent to chemotherapy, LL patients regain normality in T-cell numbers and their functions. On the other hand, the specific response of lymphocytes to M. leprae did not alter with decrease in mycobacterial load. It appears that the decrease in T-cell numbers and the deficit in their mitogenic potential is a secondary consequence of disease and is related to the antigenic load in patients with lepromatous leprosy.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 338218      PMCID: PMC1541056     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  25 in total

1.  Evidence that the mechanism of immunological tolerance ("central failure") is operative in the lack of host resistance in lepromatous leprosy.

Authors:  T Godal; B Myrvang; S S Froland; J Shao; G Melaku
Journal:  Scand J Immunol       Date:  1972       Impact factor: 3.487

2.  Mitogens as probes for immunocyte activation and cellular cooperation.

Authors:  J Andersson; O Sjöberg; G Möller
Journal:  Transplant Rev       Date:  1972

3.  Immune responsiveness to Mycobacterium leprae and other mycobacterial antigens throughout the clinical and histopathological spectrum of leprosy.

Authors:  B Myrvang; T Godal; D S Ridley; S S Fröland; Y K Song
Journal:  Clin Exp Immunol       Date:  1973-08       Impact factor: 4.330

4.  Lymphocyte activation. I. Expression of theta, H-2 and immunoglobulin determinants on lymphocytes stimulated by phytohaemagglutinin, pokeweed mitogen, concanavalin A or histocompatibility antigen.

Authors:  G Jones
Journal:  Clin Exp Immunol       Date:  1972-11       Impact factor: 4.330

5.  Blasts in lepromatous leprosy.

Authors:  E Rodriguez Paradisi; Y P de Bonaparte; M C Morgenfeld
Journal:  Lancet       Date:  1968-02-10       Impact factor: 79.321

6.  Cell-mediated immunity in patients with leprosy.

Authors:  J L Turk; M F Waters
Journal:  Lancet       Date:  1969-08-02       Impact factor: 79.321

7.  The use of enzyme markers for the identification of human peripheral B lymphocytes.

Authors:  I Nath; J Curtis; G P Talwar
Journal:  Indian J Med Res       Date:  1976-03       Impact factor: 2.375

8.  Membrane receptors and in vitro responsiveness of lymphocytes in human immunodeficiency.

Authors:  R I Schiff; R H Buckley; R B Gilbertsen; R S Metzgar
Journal:  J Immunol       Date:  1974-01       Impact factor: 5.422

9.  Lack of interaction of circulating T cells with phytohemagglutinin in bacillary positive untreated lepromatous leprosy patients--identification of subpopulation of lymphocytes by shifts in electrophoretic mobility.

Authors:  G P Talwar; S N Hanjan; V L Mehra; Z Kidwai
Journal:  J Immunol       Date:  1977-01       Impact factor: 5.422

10.  A population of lymphocytes bearing a membrane receptor for antigen-antibody-complement complexes. I. Separation and characterization.

Authors:  C Bianco; R Patrick; V Nussenzweig
Journal:  J Exp Med       Date:  1970-10-01       Impact factor: 14.307

View more
  17 in total

1.  Alterations of the immune response associated with chronic experimental leishmaniasis.

Authors:  B Arredondo; H Pérez
Journal:  Infect Immun       Date:  1979-07       Impact factor: 3.441

2.  A destiny to fulfill.

Authors:  G P Talwar
Journal:  J Biosci       Date:  2005-09       Impact factor: 1.826

3.  Tuberculous anergic sera or purified protein derivative treatment induces modification in lymphocyte transformation of cells from patients with tuberculosis.

Authors:  H Mejia-López; O Vaca-García; J M Cristerna-Aguirre; A Cruz-Chávez; M Selman-Lama; M L Taylor
Journal:  J Clin Microbiol       Date:  1990-02       Impact factor: 5.948

4.  Natural emergence of antigen-reactive T cells in lepromatous leprosy patients during erythema nodosum leprosum.

Authors:  S Laal; L K Bhutani; I Nath
Journal:  Infect Immun       Date:  1985-12       Impact factor: 3.441

5.  Studies on T cell subsets and functions in leprosy.

Authors:  M A Bach; L Chatenoud; D Wallach; F Phan Dinh Tuy; F Cottenot
Journal:  Clin Exp Immunol       Date:  1981-06       Impact factor: 4.330

Review 6.  Chemotherapy of lepromatous leprosy: recent developments and prospects for the future.

Authors:  R H Gelber
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994-11       Impact factor: 3.267

7.  Characterization of a factor in leprosy serum that inhibits the growth of mitogen-stimulated normal human lymphocytes.

Authors:  M A Kerr; Y M Hussein; R C Potts; J S Beck; M M Sheriff
Journal:  Immunology       Date:  1987-06       Impact factor: 7.397

8.  Lymphocyte transformation test in leprosy: decreased lymphocyte reactivity to Mycobacterium leprae in lepromatous leprosy, with no evidence for a generalized impairment.

Authors:  W R Faber; D L Leiker; I M Nengerman; W P Zeijlemaker; P T Schellekens
Journal:  Infect Immun       Date:  1978-12       Impact factor: 3.441

9.  T-cell recognition of mycobacterial GroES peptides in Thai leprosy patients and contacts.

Authors:  B Chua-Intra; S Peerapakorn; N Davey; S Jurcevic; M Busson; H M Vordermeier; C Pirayavaraporn; J Ivanyi
Journal:  Infect Immun       Date:  1998-10       Impact factor: 3.441

10.  Anti-hapten antibodies and autoantibodies in Japanese patients with lepromatous leprosy.

Authors:  F Furukawa; G Ohshio; M Ozaki; Y Hamashima
Journal:  Arch Dermatol Res       Date:  1984       Impact factor: 3.017

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.